Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.
Publication
, Journal Article
Lin, C; Galal, A; Rizzieri, D; Chawla, S; Lee, ST; Georgy, A; Dabovic, K; Strack, T; McKinney, M
Published in: Cancer Invest
January 31, 2023
MT-3724 is an engineered direct-kill immunotoxin comprised of a CD20-specific scFv fused to a Shiga-like toxin subunit. In this phase IIa study, eight patients with relapsed diffuse large B-cell lymphoma were treated with MT-3724 combined with gemcitabine and oxaliplatin (GEMOX). The objective response rate was 85.7%, with a median duration of response of 2.2 months. The 12-month overall survival and progression-free survival were 71.4% and 28.6%, respectively. Two patients experienced grade 2 capillary leak syndrome (CLS). Combination therapy with MT-3724 and GEMOX demonstrated an early efficacy signal but was limited by the incidence of CLS.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
January 31, 2023
Start / End Page
1 / 10
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lin, C., Galal, A., Rizzieri, D., Chawla, S., Lee, S. T., Georgy, A., … McKinney, M. (2023). Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Cancer Invest, 1–10. https://doi.org/10.1080/07357907.2022.2162073
Lin, Chenyu, Ahmed Galal, David Rizzieri, Sant Chawla, Seung T. Lee, Angela Georgy, Kristina Dabovic, Thomas Strack, and Matthew McKinney. “Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.” Cancer Invest, January 31, 2023, 1–10. https://doi.org/10.1080/07357907.2022.2162073.
Lin C, Galal A, Rizzieri D, Chawla S, Lee ST, Georgy A, et al. Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Cancer Invest. 2023 Jan 31;1–10.
Lin, Chenyu, et al. “Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.” Cancer Invest, Jan. 2023, pp. 1–10. Pubmed, doi:10.1080/07357907.2022.2162073.
Lin C, Galal A, Rizzieri D, Chawla S, Lee ST, Georgy A, Dabovic K, Strack T, McKinney M. Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Cancer Invest. 2023 Jan 31;1–10.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
January 31, 2023
Start / End Page
1 / 10
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis